Who are Taxane plus Metronomic Capecitabine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/taxane-plus-metronomic-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Taxane plus Metronomic Capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Taxane plus Metronomic Capecitabine (Taxane plus Metronomic Capecitabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane plus chemotherapy. Area: Oncology.

phase 3 Taxane plus chemotherapy Microtubules, Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Taxane plus Metronomic Capecitabine (Taxane plus Metronomic Capecitabine) — Sun Yat-sen University. Taxane inhibits microtubule dynamics, while metronomic capecitabine targets thymidylate synthase.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Taxane plus Metronomic Capecitabine TARGET	Taxane plus Metronomic Capecitabine	Sun Yat-sen University	phase 3	Taxane plus chemotherapy	Microtubules, Thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane plus chemotherapy class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Taxane plus Metronomic Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/taxane-plus-metronomic-capecitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab